← Back to Search

Other

Suvorexant for Opioid Use Disorder

Q: Are individuals aged 75 and older being accepted into this trial?

This trial specifically requires that patients are between 18 and 65 years old. For those outside of this age range, there exist 26 trials for minors and 252 studies for persons over the age of 65.

Q: Are there any enrollment opportunities remaining in this trial?

As per the clinicaltrials.gov registry, this medical trial is not currently looking for participants as it was last modified on April 25th 2023. However, there are numerous other studies that require volunteers; 299 to be exact.

Q: Can I participate in this clinical inquiry?

Eligibility requirements for this clinical trial dictate that participants must suffer from opioid use disorder and be between 18-65 years old. There is a need to recruit 75 people in total.

Phase < 1

Recruiting

Led By Justin Strickland, PhD

Research Sponsored by Johns Hopkins University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up upon completion of experimental session (~8 hours post drug administration)

Awards & highlights

Study Summary

This trial studies if a drug may reduce cravings & pleasure from other drugs, helping people reduce their use.

Who is the study for?

This trial is for adults aged 18-65 with moderate to severe Opioid Use Disorder, as defined by the DSM-5. Participants must have a history of substance use (details blinded), be in good health overall, and pass medical screenings including urine and blood tests. Those seeking opioid treatment, pregnant or breastfeeding individuals, or those with significant mental/physical disorders that could affect participation are excluded.Check my eligibility

What is being tested?

The study aims to see if suvorexant (20mg/day) can reduce usage, enjoyment, and craving for opioids compared to other undisclosed drugs (Drug A-D) and a placebo. The effectiveness of suvorexant against these blinded drugs will help understand its potential as a treatment option.See study design

What are the potential side effects?

Suvorexant may cause drowsiness, headache, dizziness, dry mouth or abnormal dreams. Since other drugs are blinded in this study, their specific side effects aren't disclosed but generally could include typical drug reactions like nausea or allergic responses.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ upon completion of experimental session (~8 hours post drug administration)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~upon completion of experimental session (~8 hours post drug administration)

This trial's timeline: 3 weeks for screening, Varies for treatment, and upon completion of experimental session (~8 hours post drug administration) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Cross-Price Elasticity

Demand Elasticity

Demand Intensity

Secondary outcome measures

Total Mean Sleep Time

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Suvorexant (20mg/day)Experimental Treatment5 Interventions

Double blind administration of suvorexant once per day during residential stay until discharge

Group II: PlaceboPlacebo Group5 Interventions

Double blind administration of placebo once per day during residential stay until discharge

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Institute on Drug Abuse (NIDA)NIH

2,470 Previous Clinical Trials

2,619,656 Total Patients Enrolled

5 Trials studying Opioid Addiction

648 Patients Enrolled for Opioid Addiction

Johns Hopkins UniversityLead Sponsor

2,266 Previous Clinical Trials

14,837,422 Total Patients Enrolled

2 Trials studying Opioid Addiction

181 Patients Enrolled for Opioid Addiction

Justin Strickland, PhDPrincipal InvestigatorJohns Hopkins University

Media Library

Suvorexant (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05829655 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are individuals aged 75 and older being accepted into this trial?

"This trial specifically requires that patients are between 18 and 65 years old. For those outside of this age range, there exist 26 trials for minors and 252 studies for persons over the age of 65."

Answered by AI

Are there any enrollment opportunities remaining in this trial?

"As per the clinicaltrials.gov registry, this medical trial is not currently looking for participants as it was last modified on April 25th 2023. However, there are numerous other studies that require volunteers; 299 to be exact."

Answered by AI

Can I participate in this clinical inquiry?

"Eligibility requirements for this clinical trial dictate that participants must suffer from opioid use disorder and be between 18-65 years old. There is a need to recruit 75 people in total."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Measuring Acute Drug Demand in Humans

2023. "Measuring Acute Drug Demand in Humans". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05829655.

All > Belsomra